{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:26:47Z","timestamp":1780396007936,"version":"3.54.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Programa Nacional de Apoio \u00e0 Aten\u00e7\u00e3o Oncol\u00f3gica","award":["Processo NUP: 25000.055356\/2015-04"],"award-info":[{"award-number":["Processo NUP: 25000.055356\/2015-04"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-91936-7","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T14:02:06Z","timestamp":1740578526000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Impact of high-sensitivity flow cytometry on peri-transplant minimal residual disease kinetics in acute leukemia"],"prefix":"10.1038","volume":"15","author":[{"given":"Ana Paula","family":"de Azambuja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam Perlingeiro","family":"Beltrame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariester","family":"Malvezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara Carolina","family":"Schluga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie Lillian Pimentel","family":"Justus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto Cardoso Martins","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaneuza Araujo Moreira","family":"Funke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmem","family":"Bonfim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Pasquini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"91936_CR1","doi-asserted-by":"crossref","unstructured":"Berry, D. A. et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: A meta-analysis. JAMA Oncol. 3, (2017).","DOI":"10.1001\/jamaoncol.2017.0580"},{"key":"91936_CR2","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","volume":"6","author":"NJ Short","year":"2020","unstructured":"Short, N. J. et al. Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: A systematic review and Meta-analysis. JAMA Oncol. 6, 1890\u20131899 (2020).","journal-title":"JAMA Oncol."},{"key":"91936_CR3","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1182\/blood-2013-06-506725","volume":"122","author":"RB Walter","year":"2013","unstructured":"Walter, R. B. et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood 122, 1813\u20131821 (2013).","journal-title":"Blood"},{"key":"91936_CR4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-580043","author":"SP Hunger","year":"2015","unstructured":"Hunger, S. P., Mullighan, C. G. & Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. Blood Preprint At. https:\/\/doi.org\/10.1182\/blood-2015-02-580043 (2015).","journal-title":"Blood Preprint At."},{"key":"91936_CR5","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/bmt.2015.103","volume":"50","author":"MA Pulsipher","year":"2015","unstructured":"Pulsipher, M. A. et al. Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested? Bone Marrow Transpl. 50, 1173\u20131179 (2015).","journal-title":"Bone Marrow Transpl."},{"key":"91936_CR6","doi-asserted-by":"crossref","unstructured":"Silva, W. F. et al. Predictive Factors and Outcomes after Allogeneic Stem Cell Transplantation for Adults with Acute Lymphoblastic Leukemia in Brazil. Transplant Cell Ther 28, 763.e1-763.e7 (2022).","DOI":"10.1016\/j.jtct.2022.07.025"},{"key":"91936_CR7","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.bbmt.2010.06.008","volume":"16","author":"N Kr\u00f6ger","year":"2010","unstructured":"Kr\u00f6ger, N. et al. NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic. Biol. Blood Marrow Transplant. 16, 1187\u20131211 (2010).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"91936_CR8","doi-asserted-by":"crossref","unstructured":"Shen, Z. et al. Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis. BMC Cancer 18, (2018).","DOI":"10.1186\/s12885-018-4670-5"},{"key":"91936_CR9","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/bjh.15086","volume":"180","author":"F Lovisa","year":"2018","unstructured":"Lovisa, F. et al. Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia. Br. J. Haematol. 180, 680\u2013693 (2018).","journal-title":"Br. J. Haematol."},{"key":"91936_CR10","doi-asserted-by":"crossref","unstructured":"Pavl\u016f, J. et al. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: A retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT. J. Hematol. Oncol. 12, (2019).","DOI":"10.1186\/s13045-019-0790-x"},{"key":"91936_CR11","doi-asserted-by":"crossref","unstructured":"Turner, M., Shah, S., Martin, A., Cong, Z. & Stein, A. S. A Systematic Literature Review (SLR) of Clinical Outcomes after Stem Cell Transplantation (SCT) in Adult Acute Lymphoblastic Leukemia (ALL) Patients with or without Minimal Residual Disease (MRD). Blood 132, (2018).","DOI":"10.1182\/blood-2018-99-112981"},{"key":"91936_CR12","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","volume":"132","author":"F Thol","year":"2018","unstructured":"Thol, F. et al. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood 132, 1703\u20131713 (2018).","journal-title":"Blood"},{"key":"91936_CR13","doi-asserted-by":"crossref","unstructured":"Zhang, Y. et al. Pretransplantation minimal residual disease monitoring by multiparameter flow cytometry predicts outcomes of AML patients receiving allogeneic hematopoietic stem cell transplantation. Transpl. Immunol. 72, (2022).","DOI":"10.1016\/j.trim.2022.101596"},{"key":"91936_CR14","doi-asserted-by":"publisher","unstructured":"Buckley, S. A. et al. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: A meta-analysis. Haematologica vol. 102 865\u2013873 Preprint at (2017). https:\/\/doi.org\/10.3324\/haematol.2016.159343","DOI":"10.3324\/haematol.2016.159343"},{"key":"91936_CR15","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2014.58.4631","volume":"33","author":"P Bader","year":"2015","unstructured":"Bader, P. et al. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the all-bfm-sct 2003 trial. J. Clin. Oncol. 33, 1275\u20131284 (2015).","journal-title":"J. Clin. Oncol."},{"key":"91936_CR16","doi-asserted-by":"publisher","first-page":"374e1","DOI":"10.1016\/j.jtct.2022.04.009","volume":"28","author":"E Klyuchnikov","year":"2022","unstructured":"Klyuchnikov, E. et al. Post-Transplantation Day\u2009+\u2009100 minimal residual disease detection rather than mixed chimerism predicts relapses after allogeneic stem cell transplantation for Intermediate-Risk acute myelogenous leukemia patients undergoing transplantation in complete remi. Transpl. Cell. Ther. 28, 374e1\u2013374e9 (2022).","journal-title":"Transpl. Cell. Ther."},{"key":"91936_CR17","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/bjh.12639","volume":"164","author":"A Balduzzi","year":"2014","unstructured":"Balduzzi, A. et al. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention? Br. J. Haematol. 164, 396\u2013408 (2014).","journal-title":"Br. J. Haematol."},{"key":"91936_CR18","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/bjh.13272","volume":"169","author":"C Pochon","year":"2015","unstructured":"Pochon, C. et al. Follow-up of post-transplant minimal residual disease and chimerism in childhood lymphoblastic leukaemia: 90 d to React. Br. J. Haematol. 169, 249\u2013261 (2015).","journal-title":"Br. J. Haematol."},{"key":"91936_CR19","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1016\/S2152-2650(20)30453-5","volume":"20","author":"L Muffly","year":"2020","unstructured":"Muffly, L. & How, I. Approach the patient who has MRD or relapse after transplant. Clin. Lymphoma Myeloma Leuk. 20, S32\u2013S33 (2020).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"91936_CR20","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1182\/blood-2015-03-580027","volume":"125","author":"JJM Van Dongen","year":"2015","unstructured":"Van Dongen, J. J. M., Van Der Velden, V. H. J., Br\u00fcggemann, M. & Orfao, A. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood 125, 3996\u20134009 (2015).","journal-title":"Blood"},{"key":"91936_CR21","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","volume":"131","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis, G. J. et al. Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD working party. Blood 131, 1275\u20131291 (2018).","journal-title":"Blood"},{"key":"91936_CR22","doi-asserted-by":"publisher","unstructured":"Borowitz, M. J., Wood, B. L., Keeney, M. & Benjamin D. Hedley Measurable residual disease detection in B-Acute lymphoblastic leukemia: the children\u2019s oncology group (COG) method. Curr. Protocols. 2 (3). https:\/\/doi.org\/10.1002\/cpz1.383 (2022).","DOI":"10.1002\/cpz1.383"},{"key":"91936_CR23","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1080\/10428194.2021.1992755","volume":"63","author":"JR Arumugam","year":"2022","unstructured":"Arumugam, J. R., Bommannan, K., Radhakrishnan, V., Sagar, T. G. & Sundersingh, S. Immunophenotypic expression and Immunomodulation in minimal residual disease analysis of pediatric B acute lymphoblastic leukemia by high sensitive flow cytometry. Leuk. Lymphoma. 63, 644\u2013652 (2022).","journal-title":"Leuk. Lymphoma"},{"key":"91936_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/cyto.b.21831","volume":"98","author":"PR Tembhare","year":"2020","unstructured":"Tembhare, P. R. et al. A High-Sensitivity 10-Color flow cytometric minimal residual disease assay in B-Lymphoblastic leukemia\/lymphoma can easily achieve the sensitivity of 2-in-106 and is superior to standard minimal residual disease assay: A study of 622 patients. Cytometry B Clin. Cytom. 98, 57\u201367 (2020).","journal-title":"Cytometry B Clin. Cytom"},{"key":"91936_CR25","doi-asserted-by":"publisher","unstructured":"Fuda, F. & Chen, W. Minimal\/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry. Current Hematologic Malignancy Reports vol. 13 455\u2013466 Preprint at (2018). https:\/\/doi.org\/10.1007\/s11899-018-0479-1","DOI":"10.1007\/s11899-018-0479-1"},{"key":"91936_CR26","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1182\/blood-2016-07-726307","volume":"129","author":"P Theunissen","year":"2017","unstructured":"Theunissen, P. et al. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood 129, 347\u2013357 (2017).","journal-title":"Blood"},{"key":"91936_CR27","doi-asserted-by":"publisher","unstructured":"Coustan-Smith, E. & Campana, D. Immunologic minimal residual disease detection in acute lymphoblastic leukemia: A comparative approach to molecular testing. Best Practice and Research: Clinical Haematology vol. 23 347\u2013358 Preprint at (2010). https:\/\/doi.org\/10.1016\/j.beha.2010.07.007","DOI":"10.1016\/j.beha.2010.07.007"},{"key":"91936_CR28","doi-asserted-by":"publisher","unstructured":"Merli, P. et al. Minimal Residual Disease Prior to and After Haematopoietic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia: What Level of Negativity Is Relevant? Frontiers in Pediatrics vol. 9 Preprint at (2021). https:\/\/doi.org\/10.3389\/fped.2021.777108","DOI":"10.3389\/fped.2021.777108"},{"key":"91936_CR29","doi-asserted-by":"publisher","unstructured":"Logan, A. C. Measurable residual disease in acute lymphoblastic leukemia: How low is low enough? Best Practice and Research: Clinical Haematology vol. 35 101407 Preprint at (2022). https:\/\/doi.org\/10.1016\/j.beha.2022.101407","DOI":"10.1016\/j.beha.2022.101407"},{"key":"91936_CR30","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1182\/bloodadvances.2019000449","volume":"3","author":"P Bader","year":"2019","unstructured":"Bader, P. et al. More precisely defining risk peri-HCT in pediatric ALL: Pre- vs post-MRD measures, serial positivity, and risk modeling. Blood Adv. 3, 3393\u20133405 (2019).","journal-title":"Blood Adv."},{"key":"91936_CR31","doi-asserted-by":"publisher","first-page":"200","DOI":"10.46765\/2675-374X.2023v4n2p200","volume":"4","author":"AJ Simione","year":"2023","unstructured":"Simione, A. J. et al. Current use and outcomes of hematopoietic stem cell transplantation: Brazilian summary slides \u2013\u20092023. J. BONE MARROW TRANSPLANTATION Cell. THERAPY. 4, 200 (2023).","journal-title":"J. BONE MARROW TRANSPLANTATION Cell. THERAPY"},{"key":"91936_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.03.001","author":"Fernandes da Silva","year":"2018","unstructured":"Fernandes da Silva et al. Treating adult acute lymphoblastic leukemia in Brazil\u2014Increased early mortality using a German multicenter acute lymphoblastic leukemia-based regimen. Clin. Lymphoma Myeloma Leuk. https:\/\/doi.org\/10.1016\/j.clml.2018.03.001 (2018).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"91936_CR33","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/08880018.2019.1636168","volume":"36","author":"JMC Rocha","year":"2019","unstructured":"Rocha, J. M. C., Xavier, S. G., Souza, M. E., de Murao, L., de Oliveira, B. M. & M. & Comparison between flow cytometry and standard PCR in the evaluation of MRD in children with acute lymphoblastic leukemia treated with the GBTLI LLA \u2013 2009 protocol. Pediatr. Hematol. Oncol. 36, 287\u2013301 (2019).","journal-title":"Pediatr. Hematol. Oncol."},{"key":"91936_CR34","first-page":"348","volume":"42","author":"KA de Silva","year":"2020","unstructured":"de Silva, K. A. Influence of minimal residual disease by multiparametric flow cytometry at day 15 of induction in risk stratification of children with B-cell acute lymphoblastic leukemia treated at a referral hospital in Southern Brazil. Hematol. Transfus. Cell. Ther. 42, 348\u2013355 (2020).","journal-title":"Hematol. Transfus. Cell. Ther."},{"key":"91936_CR35","doi-asserted-by":"crossref","unstructured":"de Melo Rodrigues, A. L. et al. Allogeneic hematopoietic stem cell transplantation for children and adolescents with acute myeloid leukemia in Brazil: A multicentric retrospective study. Cell. Transpl. 29, (2020).","DOI":"10.1177\/0963689720949175"},{"key":"91936_CR36","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1038\/s41409-021-01453-0","volume":"56","author":"V Rocha","year":"2021","unstructured":"Rocha, V. et al. Impact of mother donor, peripheral blood stem cells and measurable residual disease on outcomes after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide in children with acute leukaemia. Bone Marrow Transpl. 56, 3042\u20133048 (2021).","journal-title":"Bone Marrow Transpl."},{"key":"91936_CR37","doi-asserted-by":"publisher","first-page":"S266","DOI":"10.1016\/j.clml.2017.07.035","volume":"17","author":"C Bernardi","year":"2017","unstructured":"Bernardi, C. et al. Minimal residual disease analysis and its impact after hematopoietic stem cell transplant for acute leukemias. Clin. Lymphoma Myeloma Leuk. 17, S266 (2017).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"91936_CR38","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.bulcan.2022.02.011","volume":"110","author":"N Yafour","year":"2023","unstructured":"Yafour, N., Hamzy, F., Elkababri, M., Yakoub-Agha, I. & Bekadja, M. A. Acute lymphoblastic leukemia in developing countries: management from the transplant indication (allo\/auto) until post-transplant follow-up. Guidelines from the SFGM-TC. Bull. Cancer. 110, S30\u2013S38 (2023).","journal-title":"Bull. Cancer"},{"key":"91936_CR39","doi-asserted-by":"publisher","unstructured":"D\u00f6hner, H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood vol. 129 424\u2013447 Preprint at (2017). https:\/\/doi.org\/10.1182\/blood-2016-08-733196","DOI":"10.1182\/blood-2016-08-733196"},{"key":"91936_CR40","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMra1609337","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser, R. & Blazar, B. R. Acute Graft-versus-Host Disease \u2014 Biologic process, prevention, and therapy. N. Engl. J. Med. 377, 2167\u20132179 (2017).","journal-title":"N. Engl. J. Med."},{"key":"91936_CR41","unstructured":"EuroFlow Standard Operating Procedure (SOP) for Bulk Lysis for MRD Panels EuroFlow SOP for Bulk Lysis for MRD Panels Content. www.euroflow.org (2018)."},{"key":"91936_CR42","unstructured":"Euroflow Consortium. EuroFlow Standard Operating Procedure (SOP) for Sample preparation and staining (Version 1.5), 8. (2019). https:\/\/euroflow.org\/usr\/pub\/protocols.php"},{"key":"91936_CR43","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1038\/leu.2012.122","volume":"26","author":"T Kalina","year":"2012","unstructured":"Kalina, T. et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia 26, 1986\u20132010 (2012).","journal-title":"Leukemia"},{"key":"91936_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-024-02251-0","author":"A Sureda","year":"2024","unstructured":"Sureda, A. et al. Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT. Bone Marrow Transpl. https:\/\/doi.org\/10.1038\/s41409-024-02251-0 (2024).","journal-title":"Bone Marrow Transpl."},{"key":"91936_CR45","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner, H. et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140, 1345\u20131377 (2022).","journal-title":"Blood"},{"key":"91936_CR46","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1182\/blood.2019003566","volume":"135","author":"A Spyridonidis","year":"2020","unstructured":"Spyridonidis, A. How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation. Blood 135, 1639\u20131649 (2020).","journal-title":"Blood"},{"key":"91936_CR47","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1200\/JCO.2015.63.3826","volume":"34","author":"D Araki","year":"2016","unstructured":"Araki, D. et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? J. Clin. Oncol. 34, 329\u2013336 (2016).","journal-title":"J. Clin. Oncol."},{"key":"91936_CR48","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.clml.2014.01.002","volume":"14","author":"Y Zhou","year":"2014","unstructured":"Zhou, Y. et al. The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Clin. Lymphoma Myeloma Leuk. 14, 319\u2013326 (2014).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"91936_CR49","first-page":"295","volume":"26","author":"X Shen","year":"2021","unstructured":"Shen, X. et al. Impact of pre-transplantation minimal residual disease (MRD) on the outcome of allogeneic hematopoietic stem cell transplantation for acute leukemia. Hematol. (United Kingdom). 26, 295\u2013300 (2021).","journal-title":"Hematol. (United Kingdom)"},{"key":"91936_CR50","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.bjhh.2015.07.012","volume":"37","author":"MRV Ikoma","year":"2015","unstructured":"Ikoma, M. R. V. et al. Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia. Rev. Bras. Hematol. Hemoter. 37, 406\u2013413 (2015).","journal-title":"Rev. Bras. Hematol. Hemoter"},{"key":"91936_CR51","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/bjh.13572","volume":"171","author":"W Zeijlemaker","year":"2015","unstructured":"Zeijlemaker, W. et al. Absence of leukaemic CD34\u2009+\u2009cells in acute myeloid leukaemia is of high prognostic value: A longstanding controversy Deciphered. Br. J. Haematol. 171, 227\u2013238 (2015).","journal-title":"Br. J. Haematol."},{"key":"91936_CR52","doi-asserted-by":"crossref","unstructured":"Cloos, J. et al. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia. Journal of Visualized Experiments (2018). (2018).","DOI":"10.3791\/56386-v"},{"key":"91936_CR53","doi-asserted-by":"publisher","first-page":"E676","DOI":"10.1097\/HS9.0000000000000676","volume":"6","author":"J Tettero","year":"2022","unstructured":"Tettero, J. et al. Technical aspects of flow Cytometry-based measurable residual disease quantification in acute myeloid leukemia: experience of the European LeukemiaNet MRD working party. Hemasphere 6, E676 (2022).","journal-title":"Hemasphere"},{"key":"91936_CR54","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/leu.2015.252","volume":"30","author":"W Zeijlemaker","year":"2016","unstructured":"Zeijlemaker, W. et al. A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia. Leukemia 30, 439\u2013446 (2016).","journal-title":"Leukemia"},{"key":"91936_CR55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716863","author":"M Jongen-Lavrencic","year":"2018","unstructured":"Jongen-Lavrencic, M. et al. Molecular minimal residual disease in acute myeloid leukemia. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa1716863 (2018).","journal-title":"N. Engl. J. Med."},{"key":"91936_CR56","doi-asserted-by":"crossref","unstructured":"Svaton, M. et al. NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol. Blood 141, (2023).","DOI":"10.1182\/blood.2022017003"},{"key":"91936_CR57","doi-asserted-by":"publisher","unstructured":"Ikoma-Colturato, M. R. V. et al. Multicentric standardization of minimal\/measurable residual disease in B-cell precursor acute lymphoblastic leukaemia using next-generation flow cytometry in a low\/middle-level income country. British Journal of Haematology vol. 200 381\u2013384 Preprint at (2023). https:\/\/doi.org\/10.1111\/bjh.18499","DOI":"10.1111\/bjh.18499"},{"key":"91936_CR58","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.bbmt.2017.03.017","volume":"23","author":"BM Getta","year":"2017","unstructured":"Getta, B. M. et al. Multicolor flow cytometry and multigene Next-Generation sequencing are complementary and highly predictive for relapse in acute myeloid leukemia after allogeneic transplantation. Biol. Blood Marrow Transplant. 23, 1064\u20131071 (2017).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"91936_CR59","doi-asserted-by":"crossref","unstructured":"Caballero-Vel\u00e1zquez, T. et al. Prognostic value of measurable residual disease in patients with AML undergoing HSCT: A multicenter study. Cancers (Basel) 15, (2023).","DOI":"10.3390\/cancers15051609"},{"key":"91936_CR60","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1182\/blood.2021014804","volume":"139","author":"G Paras","year":"2022","unstructured":"Paras, G. et al. Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML. Blood 139, 1694\u20131706 (2022).","journal-title":"Blood"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91936-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91936-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91936-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T14:02:15Z","timestamp":1740578535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91936-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["91936"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-91936-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"27 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Boards of the CHC-UFPR Medical Ethics Committee under protocol number CAAE.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ana Paula de Azambuja, email apazamb@gmail.com.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Corresponding author"}},{"value":"84969718.0.000.0096, and performed following the 1964 Declaration of Helsinki.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Corresponding author"}}],"article-number":"6942"}}